Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Acamprosate/baclofen - Biosystems International/INSERM/Pharnext/University of Bordeaux

Next Previous
Search
Drug Profile

Acamprosate/baclofen - Biosystems International/INSERM/Pharnext/University of Bordeaux

Alternative Names: Acamprosate/baclofen; PXT 864

Latest Information Update: 25 Apr 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator BioSystems International; INSERM; Pharnext; University of Bordeaux
  • Developer Pharnext
  • Class Alkanesulfonic acids; Aminobutyric acids; Antidementias; Antiparkinsonians; Antispastics; Drug withdrawal therapies; Muscle relaxants; Nootropics; Small molecules
  • Mechanism of Action GABA B receptor agonists; GABA receptor agonists; Glutamate receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Alzheimer's disease
  • Phase I Amyotrophic lateral sclerosis
  • Discontinued Memory disorders; Parkinson's disease

Most Recent Events

  • 25 Apr 2023 Discontinued - Phase-I for Parkinson's disease in France (PO) (Pharnext pipeline, April 2023)
  • 07 Apr 2023 Acamprosate/baclofen is still in phase-I development for Amyotrophic-lateral-sclerosis in France (PO, Capsule) (Pharnext pipeline, April 2023)
  • 28 Oct 2019 No recent reports of development identified for phase-I development in Amyotrophic-lateral-sclerosis in France (PO, Capsule)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top